Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 5/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806214 | 0.83 | BRD4 (0.36) | BRD4RETAXLLRRK2CGAS | |
| SCHEMBL17809538 | 0.82 | ERN1 (0.47) | BRD4LRRK2CREBBPERN1TTK | |
| SCHEMBL17809543 | 0.80 | LRRK2 (0.43) | BRD4RETLRRK2CREBBP | |
| SCHEMBL17809508 | 0.73 | KDM1A (0.49) | BRD4CREBBP | |
| SCHEMBL17785849 | 0.72 | AXL (0.41) | RETAXLLRRK2CGASERN1 | |
| SCHEMBL17794670 | 0.70 | KCNH2 (0.46) | BRD4RETTTK | |
| SCHEMBL17809509 | 0.70 | WDR5 (0.56) | BRD4LRRK2CREBBP | |
| SCHEMBL23055771 | 0.69 | GRM5 (0.45) | BRD4CREBBPAURKAAURKBINCENP | |
| SCHEMBL1365942 | 0.69 | FGFR3 (0.46) | AXLERN1FGFR3KDRTTK | |
| SCHEMBL13858787 | 0.68 | FGFR3 (0.47) | RETAXLLRRK2FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | BRD4 11/4885RET 855/4885AXL 4534/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | BRD4 11/4885RET 855/4885AXL 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.